adalimumab-afzb (Abrilada) vs infliximab-qbtx (Ixifi)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-afzb (Abrilada)
Marketed by Pfizer
NCT02480153 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)
Result source: NCT02480153
infliximab-qbtx (Ixifi)
Marketed by Pfizer
NCT02222493 · Phase 3 · completed
This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.
Reported efficacy
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) (met)
Result source: NCT02222493
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-afzb (Abrilada) | infliximab-qbtx (Ixifi) |
|---|---|---|
| ACR20 | 68.3% vs 71.3%vs Adalimumab-EUNCT0248015311 other results
| 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT0222249312 other results
|
| ACR50 | 62.9% vs 55.6%vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| ACR70 | 36.4% vs 31.9%vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | -0.7 vs -0.7vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-afzb (Abrilada)
- 68.3% vs 71.3%vs Adalimumab-EUNCT02480153
11 other results
- 86.6% vs 82.2% NCT02480153
- 83.5% vs 78% NCT02480153
- 86.6% vs 84.4% NCT02480153
- 83.4% vs 77.8% NCT02480153
- 78.1% vs 73.7% NCT02480153
- 82.3% vs 78.5% NCT02480153
- 69.4% vs 68% NCT02480153
- 82.7% vs 79.3% NCT02480153
- 61.3% vs 59.7% NCT02480153
- 51.9% vs 52.3% NCT02480153
- 31.3% vs 32% NCT02480153
- infliximab-qbtx (Ixifi)
- 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT02222493
12 other results
- 60.8% vs 64.1% NCT02222493
- 63.3% vs 65.3% NCT02222493
- 73.6% vs 70.6% NCT02222493
- 76.9% vs 70.6% NCT02222493
- 71.1% vs 68.5% NCT02222493
- 69.2% vs 68.5% NCT02222493
- 64.8% vs 65.6% NCT02222493
- 57.7% vs 61.7% NCT02222493
- 71.1% vs 64.3% NCT02222493
- 70.6% vs 64.3% NCT02222493
- 52.5% vs 58.3% NCT02222493
- 32.4% vs 37.1% NCT02222493
ACR50
- adalimumab-afzb (Abrilada)
- 62.9% vs 55.6%vs Adalimumab-EUNCT02480153
11 other results
- 64.3% vs 49.6% NCT02480153
- 61.1% vs 51.9% NCT02480153
- 59.7% vs 49.6% NCT02480153
- 59.6% vs 54.7% NCT02480153
- 61.8% vs 56.3% NCT02480153
- 45.1% vs 47% NCT02480153
- 39.7% vs 39.7% NCT02480153
- 34% vs 33.3% NCT02480153
- 27.6% vs 27.3% NCT02480153
- 17.8% vs 14.3% NCT02480153
- 8.4% vs 6% NCT02480153
- infliximab-qbtx (Ixifi)
- —Not reported
ACR70
- adalimumab-afzb (Abrilada)
- 36.4% vs 31.9%vs Adalimumab-EUNCT02480153
11 other results
- 38.5% vs 32.6% NCT02480153
- 36% vs 26.7% NCT02480153
- 33.9% vs 30.4% NCT02480153
- 29.6% vs 31% NCT02480153
- 31.1% vs 30.4% NCT02480153
- 21.5% vs 22% NCT02480153
- 16.5% vs 19% NCT02480153
- 12.5% vs 11.7% NCT02480153
- 8.1% vs 8.7% NCT02480153
- 3.7% vs 3.7% NCT02480153
- 0.7% vs 2% NCT02480153
- infliximab-qbtx (Ixifi)
- —Not reported
DAS28-CRP remission
- adalimumab-afzb (Abrilada)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
HAQ-DI, change
- adalimumab-afzb (Abrilada)
- -0.7 vs -0.7vs Adalimumab-EUNCT02480153
11 other results
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.6 vs -0.6 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.4 vs -0.5 NCT02480153
- -0.3 vs -0.4 NCT02480153
- -0.3 vs -0.3 NCT02480153
- infliximab-qbtx (Ixifi)
- —Not reported
Modified Sharp score, change
- adalimumab-afzb (Abrilada)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. adalimumab-afzb (Abrilada): 3 of 5 rows · infliximab-qbtx (Ixifi): 3 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-afzb (Abrilada) | infliximab-qbtx (Ixifi) |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 83.4% (n=259) @ 78wk*a NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 216 Participants as posted | 68.3% (n=126) @ 78wk*b,a NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 86 participants as posted show 2 more doses77.8% (n=126) @ 78wk* NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 98 participants as posted 75.9% (n=253) @ 78wk* NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 192 participants as posted |
| Dropout rate | —Period 1: PF-06410293c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | —Period 1: PF-06410293c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Serious AEs | 4%Period 1: PF-06410293c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results1.4%Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 3.5%Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.4% NCT04230213 · Phase 3 | 5%Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results2.8%Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.6%Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 2.4%Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.8%Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.2%Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | c viral upper respiratory tract infection 7.1% rheumatoid arthritis 1.7% nasopharyngitis 0% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more resultsviral upper respiratory tract infection 5.3% rheumatoid arthritis 1.4% nasopharyngitis 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 nasopharyngitis 5% rheumatoid arthritis 4.7% viral upper respiratory tract infection 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | alanine aminotransferase increased 5.9% infusion related reaction 5.9% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more resultsinfusion related reaction 4.2% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 infusion related reaction 2.9% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
Notes
- aPopulation context differs: baseline_threshold differs (hscrp_mg_l>=10, swollen_joint_count>=6, tender_joint_count>=6 versus hscrp_mg_l>=8, swollen_joint_count>=6, tender_joint_count>=6).
- bThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- cPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-afzb (Abrilada)
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
+ 44 further endpoints in the CSV export.
infliximab-qbtx (Ixifi)
+ 40 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-afzb (Abrilada)'s landscape · infliximab-qbtx (Ixifi)'s landscape